Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel and Radiation for Cutaneous Angiosarcoma
NCT03921008Phase 2Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- May 2019
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in cutaneous angiosarcoma (cAS), sponsored by Washington University School of Medicine. Primary endpoint: Progression-free survival rate at 2 years. Started May 2019; status: active, not recruiting.
02
Drugs
paclitaxel
03
Conditions
cutaneous angiosarcoma (cAS)
Beyond the preview
Go deeper on NCT03921008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03921008.